Biocon Biologics
Brad Frank currently serves as the Head of Pricing and Analytics at Biocon Biologics, bringing with him extensive experience in pricing and contract strategy from previous roles at Covis Pharma, Viatris, and Mylan. Prior to their work in the pharmaceutical industry, Brad held a position as a Portfolio Manager at Huntington National Bank. Brad Frank earned their Bachelor of Science degree in Finance from West Virginia University in 2005.
This person is not in any offices
Biocon Biologics
8 followers
Biocon Biologics Limited, a subsidiary of Biocon Limited, is a fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology, and other non-communicable diseases. Six molecules from Biocon Biologics’ portfolio have been taken from lab to market in developed markets like United States, EU, Australia, Canada and Japan. With a team of ~ 4,800 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Follow-us on Twitter: @BioconBiologics